Nevro (NVRO) Competitors $4.52 +0.45 (+11.06%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NVRO vs. IRMD, AXGN, KIDS, SIBN, CATX, BFLY, TMCI, ZIMV, TCMD, and NNOXShould you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Iradimed (IRMD), AxoGen (AXGN), OrthoPediatrics (KIDS), SI-BONE (SIBN), Perspective Therapeutics (CATX), Butterfly Network (BFLY), Treace Medical Concepts (TMCI), ZimVie (ZIMV), Tactile Systems Technology (TCMD), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry. Nevro vs. Iradimed AxoGen OrthoPediatrics SI-BONE Perspective Therapeutics Butterfly Network Treace Medical Concepts ZimVie Tactile Systems Technology Nano-X Imaging Iradimed (NASDAQ:IRMD) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Which has more risk and volatility, IRMD or NVRO? Iradimed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IRMD or NVRO? 92.3% of Iradimed shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 37.1% of Iradimed shares are owned by company insiders. Comparatively, 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor IRMD or NVRO? In the previous week, Nevro had 34 more articles in the media than Iradimed. MarketBeat recorded 35 mentions for Nevro and 1 mentions for Iradimed. Iradimed's average media sentiment score of 0.84 beat Nevro's score of 0.43 indicating that Iradimed is being referred to more favorably in the media. Company Overall Sentiment Iradimed Positive Nevro Neutral Do analysts rate IRMD or NVRO? Iradimed currently has a consensus price target of $60.00, indicating a potential upside of 15.41%. Nevro has a consensus price target of $9.10, indicating a potential upside of 101.33%. Given Nevro's higher possible upside, analysts clearly believe Nevro is more favorable than Iradimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iradimed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nevro 3 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.79 Is IRMD or NVRO more profitable? Iradimed has a net margin of 26.12% compared to Nevro's net margin of -16.54%. Iradimed's return on equity of 23.99% beat Nevro's return on equity.Company Net Margins Return on Equity Return on Assets Iradimed26.12% 23.99% 20.45% Nevro -16.54%-23.52%-10.83% Which has stronger valuation & earnings, IRMD or NVRO? Iradimed has higher earnings, but lower revenue than Nevro. Nevro is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIradimed$65.56M10.05$17.19M$1.4635.61Nevro$425.17M0.40-$92.21M-$1.89-2.39 Does the MarketBeat Community prefer IRMD or NVRO? Nevro received 251 more outperform votes than Iradimed when rated by MarketBeat users. However, 64.78% of users gave Iradimed an outperform vote while only 63.67% of users gave Nevro an outperform vote. CompanyUnderperformOutperformIradimedOutperform Votes25264.78% Underperform Votes13735.22% NevroOutperform Votes50363.67% Underperform Votes28736.33% SummaryIradimed beats Nevro on 12 of the 18 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Nevro News Delivered to You Automatically Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVRO vs. The Competition Export to ExcelMetricNevroSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$169.37M$4.42B$5.16B$19.83BDividend YieldN/A41.17%5.18%3.51%P/E Ratio-2.3913.6169.0935.65Price / Sales0.4046.871,271.8617.76Price / CashN/A51.8939.7121.33Price / Book0.625.516.484.64Net Income-$92.21M$13.76M$119.82M$982.94M7 Day Performance-11.02%-6.52%-5.13%-2.12%1 Month Performance-9.24%2.19%-2.71%-0.39%1 Year Performance-72.74%50.62%31.10%23.34% Nevro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVRONevro2.7403 of 5 stars$4.52+11.1%$9.10+101.3%-73.3%$169.37M$425.17M-2.391,215Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeIRMDIradimed4.7428 of 5 stars$51.99-3.5%N/A+22.7%$658.71M$65.56M35.61110AXGNAxoGen2.8433 of 5 stars$12.64+1.4%N/A+117.9%$556.29M$159.01M-39.50426Short Interest ↓Positive NewsKIDSOrthoPediatrics4.3201 of 5 stars$22.93+1.1%N/A-26.1%$555.37M$148.73M-18.64200SIBNSI-BONE4.4134 of 5 stars$12.92+3.9%N/A-26.9%$541.87M$138.89M-14.04350Analyst ForecastAnalyst RevisionNews CoverageCATXPerspective Therapeutics2.8051 of 5 stars$7.88-11.7%N/AN/A$532.61M$1.43M0.00116Earnings ReportAnalyst RevisionNews CoverageHigh Trading VolumeBFLYButterfly Network2.9042 of 5 stars$2.35-8.2%N/A+111.7%$499.63M$76.22M-5.10460TMCITreace Medical Concepts1.057 of 5 stars$7.61-0.3%N/A-8.9%$474.08M$202.86M-7.69250ZIMVZimVie2.8711 of 5 stars$13.39-2.8%N/A+58.9%$380.31M$457.43M-1.022,600TCMDTactile Systems Technology3.9524 of 5 stars$15.66+0.2%N/A+37.5%$375.84M$274.42M24.09980NNOXNano-X Imaging2.0404 of 5 stars$5.85-3.0%N/A-8.2%$338.01M$10.13M-5.91190Upcoming EarningsNews Coverage Related Companies and Tools Related Companies Iradimed Competitors AxoGen Competitors OrthoPediatrics Competitors SI-BONE Competitors Perspective Therapeutics Competitors Butterfly Network Competitors Treace Medical Concepts Competitors ZimVie Competitors Tactile Systems Technology Competitors Nano-X Imaging Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NVRO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
